STEROID REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE (SR AGVHD)
Clinical trials for STEROID REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE (SR AGVHD) explained in plain language.
Never miss a new study
Get alerted when new STEROID REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE (SR AGVHD) trials appear
Sign up with your email to follow new studies for STEROID REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE (SR AGVHD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Last-Chance drug access for serious illnesses
Disease control AVAILABLEThis program provides access to the drug ruxolitinib for patients with serious conditions like certain blood cancers and severe graft-versus-host disease. It is for people who have no other treatment options and cannot join a standard clinical trial. The program allows doctors to…
Matched conditions: STEROID REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE (SR AGVHD)
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Lab-Made stem cells tested as rescue for dangerous transplant complication
Disease control Recruiting nowThis early-stage study is testing a new treatment for a severe complication called graft-versus-host disease (GVHD) that can happen after a bone marrow or stem cell transplant. The treatment uses special cells (iMSCs) grown in a lab from stem cells. Researchers want to see if the…
Matched conditions: STEROID REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE (SR AGVHD)
Phase: NA • Sponsor: Anhui Provincial Hospital • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC